Table 3.

Anti-diabetic drugs associated with decreased risk for LBD in the 3-year lag model

Drug name	Exposed cases	Exposed controls	Unexposed cases	Unexposed controls	OR (95% CI)	P-value	Drug class(es)
Acarbose	174	910	124 173	911 070	0.68 (0.55–0.81)	3.63E−09	Alpha-glucosidase inhibitor
Metformin HCL	12 503	83 176	111 844	828 804	0.83 (0.82–0.85)	1.48E−110	Biguanide
Sitagliptin phosphate	1401	7704	122 946	904 276	0.82 (0.77–0.86)	9.77E−20	Dipeptidyl peptidase-4 inhibitor
Sitagliptin phos/metformin HCL	280	1662	124 067	910 318	0.79 (0.70–0.89)	1.91E−06	Dipeptidyl peptidase-4 inhibitor/biguanide
Exenatide	320	2309	124 027	909 671	0.61 (0.53–0.70)	8.91E−29	Glucagon-like peptide-1 receptor agonist
Glimepiride	3260	18 889	121 087	893 091	0.88 (0.85–0.91)	2.04E−19	Sulphonylurea
Glipizide	5883	33 822	118 464	878 158	0.90 (0.88–0.92)	7.08E−21	Sulphonylurea
Glyburide	3443	19 986	120 904	891 994	0.92 (0.90–0.95)	2.51E−08	Sulphonylurea
Glipizide/metformin HCL	104	829	124 243	911 151	0.72 (0.57–0.88)	3.02E−05	Sulphonylurea/biguanide
Glyburide, micro/metformin HCL	1407	9228	122 940	902 752	0.84 (0.80–0.88)	1.05E−16	Sulphonylurea/biguanide
Glyburide/metformin HCL	536	3946	123 811	908 034	0.70 (0.63–0.77)	8.91E−23	Sulphonylurea/biguanide
Pioglitazone HCL	4356	27 795	119 991	884 185	0.80 (0.78–0.83)	5.50E−72	Thiazolidinedione
Rosiglitazone maleate	2950	18 219	121 397	893 761	0.81 (0.78–0.84)	2.69E−44	Thiazolidinedione
Rosiglitazone HCL/metformin HCL	291	2435	124 056	909 545	0.66 (0.57–0.74)	4.37E−22	Thiazolidinedione/biguanide
Rosiglitazone/metformin HCL	339	2709	124 008	909 271	0.67 (0.59–0.75)	9.12E−23	Thiazolidinedione/biguanide
Rosiglitazone/glimepiride	148	1034	124 199	910 946	0.69 (0.57–0.82)	2.40E−08	Thiazolidinedione/sulphonylurea